PARP抑制剂维利帕尼联合卡铂和吉西他滨治疗晚期卵巢癌及其他实体恶性肿瘤的I期联合研究
本研究为I期试验,确定维利帕尼联合卡铂和吉西他滨在晚期卵巢癌及其他非血液系统恶性肿瘤患者中的最大耐受剂量(MTD)和推荐II期剂量(RP2D)。75例患者入组(卵巢癌54例,乳腺癌12例),MTD/RP2D为维利帕尼250mg联合卡铂AUC 4及吉西他滨800mg/m2;在BRCA缺陷卵巢癌患者中观察到69%的缓解率(45%部分缓解,24%完全缓解)。结论认为该联合方案耐受性可,安全性特征与单用卡铂和吉西他滨相似,在携带胚系BRCA突变的铂敏感卵巢癌患者中显示出有希望的初步抗肿瘤活性。
要点
- 维利帕尼联合卡铂和吉西他滨的MTD/RP2D为维利帕尼250mg联合卡铂AUC 4及吉西他滨800mg/m2。
- BRCA缺陷卵巢癌患者中缓解率为69%(45%部分缓解,24%完全缓解)。
- 常见≥3/4级治疗相关不良事件为中性粒细胞减少和血小板减少。
核心结论
- 维利帕尼联合卡铂/吉西他滨耐受性可,安全性特征与单用卡铂和吉西他滨相似。
- 该联合方案在携带胚系BRCA突变的铂敏感卵巢癌患者中显示出有希望的初步抗肿瘤活性。
研究设计与样本
- I期研究,入组转移性或不可切除实体瘤且既往化疗方案≤2线的患者。
- 患者接受维利帕尼联合卡铂AUC 4(第1天)和吉西他滨800mg/m2(第1天和第8天),21天为一周期,最多10周期,之后可选维利帕尼维持治疗。
- 维利帕尼从第2周期第1天开始连续每日两次给药;允许使用粒细胞集落刺激因子。
- 剂量递增采用贝叶斯持续再评估法。
- 共入组75例患者(卵巢癌54例,乳腺癌12例);36例卵巢癌患者(67%)已知有胚系BRCA突变。
主要发现
- 最常见治疗相关不良事件(≥60%)为血小板减少、中性粒细胞减少、恶心和贫血。
- 最常见3/4级治疗相关不良事件(≥40%)为中性粒细胞减少和血小板减少。
- 剂量限制性毒性为血小板减少和中性粒细胞减少。
- BRCA缺陷卵巢癌患者中缓解率为69%(45%部分缓解,24%完全缓解)。
- 5例患者继续接受维利帕尼(80-310mg每日两次)超过34周期。
关键数值与推荐
- MTD/RP2D确定为维利帕尼250mg联合卡铂AUC 4及吉西他滨800mg/m2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of veliparib combined with carboplatin and gemcitabine in patients with advanced ovarian cancer and other nonhematologic malignancies. METHODS: In this phase I study, patients with metastatic or unresectable solid tumors and ≤2 prior chemotherapy regimens received veliparib combined with carboplatin area under the curve (AUC) 4 on day 1 and gemcitabine 800mg/m2 on days 1 and 8 of a 21-day cycle for maximum 10cycles, followed by optional veliparib maintenance therapy. Veliparib dosing commenced twice-daily (BID) continuously on day 1 of cycle 2; granulocyte colony-stimulating factor was permitted. Dose escalation used a Bayesian continual reassessment method. Safety, tolerability, and efficacy were evaluated. RESULTS: Seventy-five patients were enrolled (ovarian cancer, n=54; breast cancer, n=12). Thirty-six patients with ovarian cancer (67%) had known germline BRCA mutations. Most common treatment-related adverse events (TRAEs; ≥60%) were thrombocytopenia, neutropenia, nausea, and anemia. Most common grade 3/4 TRAEs (≥40%) were neutropenia and thrombocytopenia. Dose-limiting toxicities were thrombocytopenia and neutropenia. The MTD/RP2D was established at veliparib 250mg with carboplatin AUC 4 plus gemcitabine 800mg/m2. Responses were observed in 69% of patients with BRCA-deficient ovarian cancer (45% partial, 24% complete responses). Five patients remained on veliparib (80-310mg BID) for >34cycles. CONCLUSIONS: Veliparib plus carboplatin/gemcitabine is tolerated, with a safety profile similar to carboplatin and gemcitabine alone. Combination therapy demonstrated promising preliminary antitumor activity in platinum-sensitive ovarian cancer patients with germline BRCA mutations. Trial registration ID: NCT01063816.
引用
- Gray HJ, Bell-McGuinn K, Fleming GF, et al. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018. PMID: 29352572. doi:10.1016/j.ygyno.2017.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。